Tranzyme Kills TZP-102 Study
DURHAM, N.C. (AP) - Tranzyme has announced the end of a mid-stage study of a treatment for diabetic gastroparesis because it failed to outperform a placebo.
The Durham, N.C., company said the study involved three daily doses of its treatment, labeled TZP-102. Last month, the company said a once-daily dose of TZP-102 also did not work better than a placebo at treating the condition.
Gastroparesis is a condition in which the stomach takes too long to clear out food. Tranzyme has said it affects about 12% of people with diabetes. It causes nausea, vomiting, dehydration, and difficulty digesting food.
TZP-102 is Tranzyme's most advanced drug candidate, and the company also is studying it as a possible treatment for other intestinal disorders. It also is studying another drug, TZP-201, as a treatment for diarrhea caused by chemotherapy.
Date: December 17, 2012
Source: Associated Press